Key Highlights
- Shares trading down 1.80% to $0.92 in today's session.
- Trading Volume reached 195.21 thousand shares.
- The company reported a forward P/E ratio of 5.25 and an EPS of negative $0.55.
- The filing is backed by Phase 3 data showing 45.6% complete lesion clearance versus 16.7% on placebo.
FDA Filing Seeks Full-Body Treatment Expansion
Biofrontera Inc. (NASDAQ:BFRI), a dermatology-focused biopharmaceutical company, filed a supplemental application with the FDA to expand use of its approved skin treatment, Ameluz, combined with red light therapy, to cover actinic keratoses on the arms, legs, neck, and trunk, not just the face and scalp. If approved, the expansion would make Ameluz the only such therapy approved in the US for treating this condition across the full body.
Phase 3 Data Supports the Submission
The filing is backed by a Phase 3 trial in which 45.6% of treated patients achieved complete lesion clearance after 12 weeks, compared with 16.7% on a placebo treatment. The trial evaluated treatment fields of up to approximately 240 square centimeters using the company's existing lamp and gel combination.
Shares Slip Despite Recent Revenue Growth
Despite today's regulatory news, shares dipped slightly, with a forward P/E ratio of 5.25 and an EPS of negative $0.55 reflecting the company's current financial position. The company has reported revenue growth of about 25% for the first half of 2026, following a recent approval for a related skin condition in September.
Outlook: Label Expansion Could Broaden Addressable Market
If approved, the expanded indication would allow dermatologists to treat a broader patient population using equipment many practices already have installed. The filing follows closely on the heels of the company's recent approval for superficial basal cell carcinoma, continuing its strategy of broadening its existing platform's label.






Please wait processing your request...